Common variable immunodeficiency (CVID) is a heterogeneous primary immunodeficiency disorder (PID) characterized by low serum concentrations of immunoglobulins and impaired specific antibody production. [1] [2] [3] Specific antibody deficiency is a diagnostic criterion in most of the standard clinical guidelines and constitutes the absence of natural immunoglobulins (eg, isohemagglutinins) or poor response to novel protein or polysaccharide antigens (eg, in vaccines). 2, 4, 5 Approximately 10% to 20% of patients with a clinical diagnosis of CVID have a residual response to vaccination against protein antigens and, to a lesser extent, against polysaccharide antigens. [6] [7] [8] [9] [10] [11] [12] The heterogeneity in specific antibody defects in patients with CVID might be due to the association of this complex disease with several different genetic defects. 13, 14 Although it is uncertain whether vaccination with killed/ inactivated vaccines will protect a patient with CVID, the use of these vaccines is nevertheless recommended for diagnostic purposes. 10, 15 Moreover, use of killed/inactivated vaccines in patients with PIDs is recommended to follow the same schemes as in general populations. 16 Current evidence suggests that a subgroup of patients with CVID is not only capable of restimulation in vitro for production of class-switched immunoglobulins but also can show residual antibody production in vivo. [17] [18] [19] Characterization of this subgroup of patients regarding their clinical, immunologic, and genetic profile could potentially help develop targeted therapy for these patients 18, 20 and provide evidence-based advice regarding administering influenza vaccine to patients with CVID.
To our knowledge, the immunologic response to the same antigen as used in the current study, A(H1N1) pandemic influenza vaccine (antigen X179a 2009, Pandemrix; GlaxoSmithKline, Wavre, Belgium), has thus far only been investigated in 3 patients with CVID and 1 patient with X-linked agammaglobulinemia in a 3-month-long follow-up study. 19 Two of the patients with CVID responded to the vaccination with a greater than 4-fold increase in levels of hemagglutination inhibition antibodies, and all 3 showed a T H 1 cell response. It was concluded that some patients with CVID might produce an influenza-specific humoral immune response but that this should be confirmed in larger studies.
The aim of the study was to try to identify clinical, immunologic, and genetic predictive markers for those patients with CVID who had a humoral immune response after influenza vaccination. This was performed by investigating to what extent a group of patients with CVID responded to vaccination by producing protective antibodies against the glycopeptide pandemic influenza A(H1N1) antigen.
METHODS
The present study had a prospective design, monitoring patients with CVID before and up to 1 year after vaccination with the pandemic influenza A(H1N1) vaccine (Pandemrix).
Patients
Patients with CVIDs cared for and receiving immunoglobulin replacement therapy at the Immunodeficiency Unit at the Karolinska University Hospital, Stockholm, Sweden, and who had not already been vaccinated against the A(H1N1) pandemic virus were invited to participate in the study carried out during 2010-2011. None of the patients used any steroids or any other immunosuppressive therapies during the study period and 3 months before the study's start. All patients had received a diagnosis of CVID based on the diagnostic criteria established by the European Society for Immunodeficiencies (http://esid.org/WorkingParties/Registry/Diagnosis-criteria) and the American Academy of Allergy, Asthma & Immunology practice parameter for the diagnosis and management of PIDs. 4, 21 Before the study's start, all patients were re-evaluated for fulfilling the diagnostic criteria of CVID, and secondary causes of dysgammaglobulinemia were ruled out. 22 None of the invited patients presented with protein-losing enteropathy or prestudy protective A(H1N1) pandemic virus antibody (> _1:40 titer).
Fifty-seven patients provided informed consent and volunteered to participate in the study by receiving the first dose of vaccine. Nine patients (5 women and 4 men; mean age, 48.8 6 20.3 years) dropped out of the study: 7 at the first follow-up visit and 2 at the second follow-up visit. In total, 48 patients (60.4% female patients) participated in all appointments and were included in the final vaccine response analyses. Forty-seven of the patients received regular weekly subcutaneous (minimum, 100 mg/kg/wk) and 1 patient received monthly intravenous (400 mg/kg/mo) immunoglobulin replacement therapy before and during the entire study period. Different brands were used, but each patient received the same brand and batch of immunoglobulins at least 3 months before and at least until the last blood sampling.
An evaluation document was used to summarize the demographic information of each patient, including age at diagnosis, family history and history of previous vaccinations shown as specific antibody responses, and clinical, immunologic, and genetic data.
Study overview
The A(H1N1) pandemic influenza vaccine Pandemrix, a monovalent X179a 2009 vaccine, was injected intramuscularly at the study's start and boosted once after 1 month. In each vaccination dose, 3.75 mg of hemagglutinin (HA) of the X179a antigen was administered. At the study's start, concentrations of total IgG, IgG subclasses, IgA, and IgM were determined in fresh serum samples taken immediately before the next immunoglobulin substitution. Specific antibody titers for antibodies against the pandemic influenza A(H1N1) antigen were measured in samples collected before the first and second vaccinations and also 2 months after the second dose. Follow-up visits due to the vaccine study were scheduled for the patients at regular intervals until 1 year after the study's start for the recording of any influenza-like symptoms and/or incidental side effects of the vaccination.
Investigation and definition of vaccination response
One volume of serum was treated with 4 volumes of neuraminidase receptor-destroying enzyme (Seiken, Tokyo, Japan) in PBS at 378C overnight before inactivation at 568C for 30 minutes to prevent nonspecific inhibition. Serial 2-fold dilutions of receptor-destroying enzyme-treated sera were then incubated with 8 hemagglutinating units of the X179a pandemic influenza A(H1N1) antigens for 1 hour, followed by the addition of 0.7% ([Volume of solute/Volume of solution] 3 100%) turkey erythrocytes. After 30 minutes of incubation, the HA inhibition titers were read as the reciprocal of the highest dilution at which 50% HA was inhibited. Each serum sample was run in duplicate in 2 independent experiments, and the titers are presented as a mean of these 2 experiments for each patient.
A positive response to the pandemic influenza A(H1N1) antigen was defined as at least a 4-fold titer increase in results of the HA inhibition test (> _1:40). 23 Patients with such an increase are hereafter referred to as responders.
Clinical and immunologic phenotyping and immunologic assays
Clinical phenotyping of the 48 patients was based on the suggested division into distinct clinical phenotypes by Chapel et al 24 and included patients with infections but no other disease-related complications or patients with infections and autoimmunity, infections and enteropathy, and/or infections and polyclonal lymphocytic infiltration. Patients with 3 or more clinical findings were classified as overlapping phenotypes. Clinical data were collected from the medical and nursing records and covered the time from diagnosis to the study's start.
Thirty-eight of the patients had been classified previously based on 2 main classifications for B-cell subsets, including the Paris, Freiburg, EUROclass, 25 and B-cell pattern 26 classifications. In 27 of the patients, ionizing radiation sensitivity assays had been performed previously on primary fibroblasts irradiated with different doses and serial dilutions. 27 This is a method used for classification of patients with CVID and defective DNA repair machinery required for variable (V), diversity (D), and joining (J) gene rearrangement and class-switch recombination. [28] [29] [30] [31] PBMCs from all 48 patients were stimulated for 48 hours with PHA, and cytokine production of IFN-g, IL-2, IL-5, IL-10, and IL-12 was measured by means of ELISA with a previously described method. 32 Screening of positional candidate genetic markers HLA-A, HLA-B, HLA-DQ, and HLA-DR alleles were determined by using low-resolution DNA-based typing (PCR/sequence-specific oligonucleotide probe). 33 PCR amplification of TNF receptor superfamily members 13B and 13C (TNFRSF13B and TNFRSF13C) and Sanger sequencing were performed by using primers and conditions, as previously described. 34 Of note, selected monogenic forms of PIDs were excluded in studied patients according to the CVID diagnostic criteria by using a targeted gene panel sequencing (covering 260 known monogenic diseases), including BTK, BLNK, CD79A, CD79B, IGHM, IGLL1, TCF3, CD19, CD20, CD21, CD81, AICDA, UNG, INO80, MSH6, CARD11, NFKB1, NFKB2, PI3KCD, PIK3R1, PTEN, DOCK2, IKAROS, IRF2BP2, MOGS, TWEAK, IL21, IL21R, LRBA, and CTLA4 genes. Moreover, whole-exome sequencing in 17 patients was also performed, but neither nonresponders nor responders had a confirmed candidate monogenic disease.
Ethical considerations
The World Health Organization declared in June 2009 that the outbreak of A(H1N1) influenza fulfilled the criteria of a pandemic situation. As a consequence, the National Board of Health and Welfare in Sweden recommended the general population to be vaccinated and certain risk groups, including subjects with an impaired immune system, to be prioritized. The pandemic influenza A(H1N1) vaccine had not been used previously in a mass vaccination situation, but the potential severity of the disease motivated patients with CVID to be offered the new vaccine.
Based on the Ethical Review of Research Involving Humans, 35 the vaccination schedule, including blood sampling and follow-up schedules, was approved by the regional Ethical Committee (approval no. 2009/1646-31-3). The patients were given oral and written information about the study. The principle of volunteering was emphasized, and written informed consent to participate, including a 1-year follow-up, was obtained from all patients.
Statistical analyses
Statistical analyses were performed with SPSS (version 21.0.0; SPSS, Chicago, Ill) and R statistical systems (version 3.4.1.; R Foundation for Statistical Computing, Vienna, Austria) software. The 1-sample Kolmogorov-Smirnov test was applied to estimate whether data distribution was normal, and based on the findings of this evaluation, independent t tests (in normal distributions) and Mann-Whitney U tests (in skewed distributions) were used to compare continuous variables between responders and nonresponders. Differences in categorical variables between responders and nonresponders were examined by using x 2 and Fisher exact tests (the latter when variables had a low frequency). Pearson correlation coefficient analysis was used to investigate the relationship between specific antibody responses to different antigens. A P value of .05 or less was considered statistically significant.
RESULTS
Three months after the first vaccine dose and 2 months after the second dose, 8 (16.7%) patients had reached a 1:40 or greater titer of specific antibodies against the pandemic influenza A(H1N1) antigen (responders), whereas the remaining 40 (83.3%) patients were considered nonresponders. Production of specific antibodies against the antigen is depicted in Fig 1. Four of 8 responders reached protective levels already after the first vaccine dose. Comparing the 4 early responders with the 4 late responders, no significant differences could be found between their current age (57.0 6 14.7 vs 54.2 6 11.7 years) or age at CVID diagnosis (41.5 6 10.0 vs 39 6 16.8 years).
During the study period, none of the patients showed any clinical symptoms of having been infected with the ongoing pandemic influenza A(H1N1), and during the 1-year follow-up period, no influenza-like symptoms and/or negative side effects other than local reactions at the injection site were reported. Table I summarizes the demographic and essential immunologic data of responders and nonresponders. Response to the A(H1N1) pandemic vaccine was independent of the sex of the patients. There were also no significant differences in mean age at diagnosis, mean age at the study's start, mean years from onset of infection to diagnosis, or mean follow-up time after the CVID diagnosis between responders and nonresponders, respectively. Nine patients had a familiar form of CVID, all belonging to the nonresponder group. In the total group 14 (29.1%) subjects evolved from an IgA deficiency (n 5 12) and/or IgG subclass deficiency (n 5 2) to a CVID diagnosis during the course of their disease. All 14 of these patients were nonresponders, constituting 35.0% of this group (P 5 .048 compared with absence of this progressive PID form in responders, Table I ).
Regarding immunoglobulin replacement therapy, there was no difference in the distribution of different immunoglobulin brands used between responders and nonresponders (data not shown).
Clinical phenotyping
Before diagnosis, all 48 patients experienced recurrent upper respiratory tract infections, and 38 had also been given a diagnosis of recurrent lower respiratory tract infection (bronchitis, pneumonia, or both). Clinical phenotyping of the 48 patients revealed that 14 (29.2%) of them presented with infections without any other disease-related complications; 14 (29.2%) by infections and autoimmunity, 4 (8.3%) by infections and enteropathy, and 3 (6.2%) by infections and polyclonal lymphocytic infiltration. Thirteen (27.1%) patients also manifested overlapping phenotypes (see Table E1 in this article's Online Repository at www.jacionline.org).
When dividing clinical phenotyping between responders and nonresponders, the proportion of patients with infections without any other disease-related complications was 12.5% among responders and 32.5% among nonresponders (P 5 .12; Fig 2  and see Table E1 ). Lower respiratory tract infections were documented in 5 (62.5%) responders and in 33 (82.5%) nonresponders (P 5 .20). None of the responders showed signs of bronchiectasis, whereas 7 (17.5%) nonresponders (P 5 .10) had this condition (see Table E1 ).
The phenotype of infections and enteropathy was significantly more frequent in responders (50% vs 0%, P <.001) and infections and autoimmunity were present in about the same proportion in both groups (25% in responders and 30% in nonresponders, not significant; Fig 2 and see Table E1 ), whereas autoimmune cytopenia was exclusively observed among the nonresponders (n 5 5) (see Table E1 ).
Malignancies were recorded in 12 (30%) patients among the nonresponders, mainly because of thymoma and lymphoma, and in 2 (25%) patients among the responders (1 with breast cancer and 1 with colon cancer, P 5 .38; see Table E1 ).
No significant difference was observed regarding the proportion of patients with IgE-mediated atopic disorders: 4 (50%) responders and 9 (22.5%) nonresponders (P 5 .12, see Table E1 ).
Immunologic phenotyping and classification
At the time of the CVID diagnosis, a significantly greater mean serum level of IgM (34.8 6 29.6 vs 17.0 6 16.0 mg/dL, P 5 .03) and a significantly lower mean serum level of IgG 1 (122.4 6 96.3 vs 219.2 6 198.3 mg/dL, P 5 .007) were noted in nonresponders compared with responders. Lymphocyte subset analyses showed an expansion of absolute counts of cytotoxic T cells (P 5 .033), as well as an increased proportion of memory CD8
1 T cells (P 5 .044) in nonresponders compared with responders. Furthermore, there was a tendency for a greater number of natural killer cells among nonresponders compared with responders (P 5.06). There was no significant difference between responders and nonresponders regarding absolute B-cell counts, although the nonresponders presented with a decreased number of plasmablasts and an increased CD21 low percentage (P 5 .007 and P 5 .041, respectively; Table II) . Radiosensitivity was documented only in the group of nonresponders (4/20 [20%] tested nonresponders vs 0/7 tested responders, P 5 .09).
Although a positive correlation was observed in responders with increments in the level of protective antibodies after vaccination with the pandemic influenza A(H1N1) antigen regarding production of other specific antibodies against protein and polysaccharide antigens (r 5 0.75, P 5 .08), no statistically significant differences were found between responders and nonresponders. Details of the humoral immune response to other antigens are presented in Table E2 in this article's Online Repository at www.jacionline.org. Fig 3) .
PHA-induced cytokine production in vitro in responders and nonresponders is presented in Fig 4. A significant difference was found in mean IL-12 levels: 108.1 6 65.1 pg/mL in nonresponders and 28.3 6 25.6 pg/mL in responders (P 5 .007).
Genetic markers associated with CVID and pandemic influenza A(H1N1) antibody production Four (10%) patients with TNFRSF13B and 1 (2.5%) patient with TNFRSF13C CVID susceptibility variants were found among the nonresponders, whereas only wild-type TNFRSF13 genes were identified among the responders (12.5% vs 0%, P 5 .38). HLA markers associated with CVID were detected in 16 (40%) of 40 of the nonresponders: HLA-DR3-DQ2 in 6 patients, HLA-A1-B8 in 6 patients, and HLA-A2-B44 in 4 patients. HLA markers associated with CVID were not found in any of the responders (40% vs 0%, P 5 .03).
DISCUSSION
The outbreak of the pandemic influenza A(H1N1) virus and the recommendation to specifically vaccinate persons with an impaired immune system not only stressed the immediate medical need to offer this new vaccine with a A(H1N1) clade selected by the World Health Organization to patients with CVID but also opened up a possibility for a scientific evaluation of vaccination in this group of subjects. The background to the study was the perpetual discussion of whether patients with CVID should be offered routine vaccination against seasonal influenza. Only our study and the study by Pedersen et al 19 have presented data from use of the specific antigen X179a to patients with CVID. Our study was designed as an evaluation within the patient group, and therefore no healthy control subjects were included. However, it has been shown that between 67% and 98.3% of healthy adults produce protective levels of antibodies against the influenza A(H1N1) vaccine Pandemrix 21 days after a single dose of 3.75 mg of the vaccine. 36, 37 Cross-reactive A(H1N1) antibodies are present in healthy populations, 38 and consequently, antibodies against the pandemic influenza A(H1N1) antigen might be present in immunoglobulin preparations. 39 Therefore all participants in the study were tested for pre-excising A(H1N1) antibodies before entering the study. One 73-year-old man had an HA inhibition titer of 1:10 at the study's start, but this patient did not respond to vaccination. All patients continued with the same brand and batch of immunoglobulin during the study period.
The World Health Organization declaration in 2009 of a pandemic situation in 74 countries and territories rapidly led to a demand for the vaccine that was greater than the supply. On a European level, it was considered important to offer the vaccine rapidly to as many subjects as possible. For this reason, it was Table E1 ). PLI, Polyclonal lymphocytic infiltration.
decided by the authorities to start the vaccination campaign with an antigen dose of 3.75 mg to the entire population, but immunodeficient patients were to be offered a second dose after 1 month. Later it was shown that a single dose of 3.75 mg of Pandemrix with the antigen X179a brings about immunity to a protective level in healthy adults and the elderly. 40 In the study by Pedersen et al 19 about the immunologic response to the antigen X179a in CVID, the intention was to give 2 doses of 3.75 mg to 3 patients with CVID, but the patients were accidentally given a double dose of Pandemrix at the study's start. Two of the patients were then given a second dose of 3.75 mg after 3 weeks, whereas the third patient declined being given the second dose. The 2 patients receiving 2 doses (7.5 mg 1 3.75 mg) responded with a greater than 4-fold humoral response, whereas the patient receiving 1 dose (7.5 mg) had a hemagglutination inhibition titer of less than 1:40.
In our study 4 of the responders had protective levels of antibodies against the X179a antigen already after 1 dose of 3.75 mg, whereas the 4 others needed 2 doses to produce protective levels of antibodies (Fig 1) . The 4 early responders were not older at diagnosis or the study's start than the 4 late responders, which could have explained the result because older patients might have been in contact with cross-reactive antigens earlier. Based on the current study and the study by Pedersen et al, 19 it seems reasonable to assume that 2 doses of 3.75 mg of the antigen X179a would be required to obtain humoral immunity in patients with CVID. Whether these patients should be offered 1 or 2 doses of inactivated seasonal influenza vaccine has never been addressed in the 4 groups of patients with CVID in which the outcome of this type of vaccine has been investigated, 9, 17, 41, 42 and therefore any answer to this question is not available.
However, Eibl and Wolf 16 suggest that the primary immunization of inactivated influenza vaccine should follow the same scheme as for healthy subjects but that more frequent booster immunizations might be necessary depending on the assessment of vaccination response in patients with PIDs.
The influenza, polysaccharide, or protein vaccine studies that have been conducted in patients with CVID 7, 9, 19, [41] [42] [43] [44] have shown more frequent and earlier decreases in antibody responses against polysaccharides compared with proteins, suggesting preservation of a T cell-dependent specific antibody response in a subgroup of patients. 7, 19, 43 In a previous study, Zhan et al 41 reported generation of specific IgG-secreting memory B cells after seasonal influenza vaccines in 50% of the studied patients with CVID. In our study we found that about one fifth (16.7%) of the patients responded by producing protective levels of antibodies against the pandemic influenza A(H1N1) antigen. Consistent with other reports, we also observed a functional classification of patients with CVID, according to the level of vaccine response. 43, 45 To date, there are no studies regarding the clinical phenotypes of patients who seroconvert or not after influenza vaccination. 46 Findings among the responders of a significantly higher proportion of enteropathies, a phenotype that usually presents as a result of increased apoptotic bodies in the gastrointestinal crypts, 47 might suggest that the immunologic phenotype of the responders with normal B-cell subsets could be a result of increased apoptosis of the long-term plasma cells. In line with this notion, these patients can produce normal antibodies against specific antigens in the short term, but these antibody-producing plasma cells subsequently disappear. The increased susceptibility to apoptosis in the gastrointestinal crypts could be a trigger of NK, Natural killer. *P values of less than .05 were regarded as significant and are shown in boldface.
J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 6 chronic inflammation. Regarding the severe lower respiratory tract infections and bronchiectasis among nonresponders, it appears that the nonresponders are less likely to mount an immune response against bacteria and, consequently, effective elimination in the lower respiratory tract, resulting in persistent tissue damage in the lungs. The capability to respond to certain vaccines in vivo suggests strongly that some patients with CVID can produce class-switched isotypes, as has been shown by using cytokine stimulation in vitro. 48 Although CD27 norm and post-germinal center B-cell pattern). In contrast, at diagnosis, we found that the nonresponders presented with lower mean serum levels of IgG 1 and higher mean serum levels of IgM, highlighting severe defective class-switch recombination in this group of patients. Moreover, radiosensitivity was only found in nonresponders, but this test was performed only in 27 patients, and the difference was not statically significant. These findings emphasize the role of the class-switching capability for developing a vaccine response. Two studies by Goldacker et al 7 and Chovancova et al 13 presented B-cell subset analysis; both reported that group II of the Freiburg classification or the EUROclass group smB 1 , which represent patients with CVID with nearly normal numbers of class-switched memory B cells, constitutes patients with measurable antibody responses.
Stimulating PBMCs with PHA enhanced IL-12 production at a significantly higher mean level in nonresponders compared with responders, suggesting significant immune regulation in this group toward activation of cellular immunity. Upregulation of IL-12 as an initial factor in a subgroup of patients with CVID skews the immune response away from immunoglobulin production toward polarized T H 1-type chronic inflammation. 50, 51 Increased expression of the IL-12b1 receptor has also been reported in these patients. 52 Although IFN-g levels, another marker of the T H 1 response, did not differ between the 2 groups, immunoglobulin replacement can alter the serum pattern of this cytokine but not the IL-12 level. 53 Failure of an immune deviation from a systemic T H 1 response to a T H 2 immune response might explain the mechanism responsible for the numerically lower proportion of IgE-mediated atopic diseases observed in nonresponders compared with responders. 54 Humoral response against influenza vaccine has been shown to be the major source of protection against infections, and subjects receiving annual injections have a broader antibody recognition profile after pathogenic confrontation. 55 However, influenzaspecific CD8
1 T cells can be generated after vaccination targeted to conserved viral proteins (nucleoprotein and the matrix protein) to provide heterosubtypic immunity. Because long-term annual vaccination in the presence of normal humoral immunity can interfere with induction of heterosubtypic immunity, it can be hypothesized that virus-specific CD8
1 T-cell responses are more pronounced in patients with antibody deficiency. 56 Because the current study only focused on humoral immunity, further evaluation of cellular immunity in these patients might be of considerable interest.
The presence of the familiar form of CVID only in nonresponders, together with the finding of predisposing HLA and non-HLA factors, suggests a strong association of CVID pathogenesis in this group of patients. 57 Moreover, progressive primary antibody deficiency was found exclusively in nonresponders, a phenomenon that has been linked previously to genetic susceptibility markers in patients with CVID, in particular HLA-A1, HLA-B8, HLA-DR3, and HLA-DQ2.
58,59
Investigation of nongenetic causes among responders should be prioritized, including epigenome and microbiome assays. The essential role of the specific HLA haplotype in response to vaccine has been investigated also in healthy subjects; in particular, CVID HLA susceptibility markers, such as DQ2-DR3 phenotypes, have been linked with nonresponsiveness to hepatitis B antigen in vaccine in the healthy population. 60, 61 Specific antibody response to vaccines has also been investigated in patients with TNFRSF13B-mutated alleles and transmembrane activator and CAML interactor (TACI) knockout mice because of the role of TACI in signaling for induction of immunoglobulin class-switching. Most of the animal studies have showed consistent defective responses to vaccination with T-independent antigens. 62 However, human subjects with heterozygous TNFRSF13B mutations show a wide range of ability to respond to vaccine from absent to some antibody production, 63, 64 even within the same family with same mutation, 65 suggesting the presence of a different genetic modifier rather than TACI.
In summary, we identified protective increments in antibody levels against the pandemic influenza A(H1N1) antigen in 8 (16.7%) patients of our study population, including 48 subjects. To date, this is the largest study performed investigating influenza vaccine response in patients with CVID. We found that a positive outcome of influenza vaccination might be expected in patients with certain identified specific B-cell patterns. The responders were sporadic cases without genetic susceptibility markers but with normal class-switch recombination and DNA repair machinery. Therefore they could still produce residual specific antibodies against the current antigen and presented with a low rate of severe lower respiratory tract infections and no infectious complications, such as bronchiectasis. Instead, these patients more often presented with enteropathy.
Predictive markers for patients with CVID who will respond to influenza vaccine were found to be enteropathy, EUROclass SmB 2 Tr norm 21 norm , and post-germinal center B-cell pattern. Despite the fact that not all patients with CVID had protective antibody levels after 2 doses of the vaccine, it is concluded that patients with CVID should be offered vaccination also against seasonal influenza 9, 16, 17, 42, 46 because of the potential severity of the infection and risk for bacterial complications. Adverse events are not a major issue, and inactivated influenza vaccine can be administered safely to patients with CVID. production, and T H 1 polarity were observed only in nonresponders.
d Despite the fact that not all patients with CVID will have protective antibody levels after influenza vaccination, it is concluded that they should be offered this prophylactic measure because of the potential severity of influenza and risk for bacterial complications. 
